« Back to Medicines list

Versatis 700 mg medicated plaster

  • Name:

    Versatis 700 mg medicated plaster

  • Company:
    info
  • Active Ingredients:

    Lidocaine

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 03/08/18

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 24/7/2018

Click on this link to Download PDF directly

Grunenthal Pharma Ltd.

Grunenthal Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Ixprim effervescent tablets Active Ingredients Paracetamol, Tramadol Hydrochloride
Medicine Name Ixprim film coated tablets Active Ingredients Paracetamol, Tramadol Hydrochloride
Medicine Name Palexia 100 mg film-coated tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia 50 mg film-coated tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia 75 mg film-coated tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia Oral Solution 20 mg/ml Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia SR 100 mg prolonged-release tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia SR 150 mg prolonged-release tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia SR 200 mg prolonged-release tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia SR 250 mg prolonged-release tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Palexia SR 50 mg prolonged-release tablets Active Ingredients Tapentadol hydrochloride
Medicine Name Qutenza 179mg Cutaneous Patch Active Ingredients Capsaicin
Medicine Name Versatis 700 mg medicated plaster Active Ingredients Lidocaine
Medicine Name Zomig 2.5mg Tablets Active Ingredients Zolmitriptan
Medicine Name Zomig Rapimelt 2.5mg Active Ingredients Zolmitriptan
Medicine Name Zydol 100mg Solution for Injection Active Ingredients Tramadol Hydrochloride
Medicine Name Zydol 50mg caps Active Ingredients Tramadol Hydrochloride
Medicine Name Zydol SR 100mg Active Ingredients Tramadol Hydrochloride
Medicine Name Zydol SR 100mg, 150mg, 200mg Tablets Active Ingredients Tramadol Hydrochloride
Medicine Name Zydol SR 150mg Active Ingredients Tramadol Hydrochloride
Medicine Name Zydol SR 200mg Prolonged Release Tablets Active Ingredients Tramadol Hydrochloride
Medicine Name Zydol SR 50mg Active Ingredients Tramadol Hydrochloride
1 - 0 of 22 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 3 August 2018

Updated on 27 July 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number

Updated on 24 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 6 July 2018 SmPC

Reasons for updating

  • Change to section 9 - Date of first authorisation/renewal of the authorisation

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Date of last renewal updated

Updated on 7 February 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 7 February 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 7 February 2018 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 1: Name of Medicinal product    - change in expression of strength from 5% to 700mg 'Versatis 5% 700mg medicated plaster'

Section 2: Qualitative and quantitative composition     - '50mg lidocaine per gram adhesive' has been deleted. E numbers for methyl parahydroxybenzoate, propyl parahydroxybenzoate and propylene glycol added.

Section 4.4: Special warning and precautions for use    - E numbers for methyl parahydroxybenzoate, propyl parahydroxybenzoate and propylene glycol added.

Section 5.1: Pharmacodynamic properties    - reference to 5% replaced with 700mg

Section 5.2: Pharmacokinetic properties        - reference to 5% replaced with 700mg

Section 6.1: List of excipients            - liquid sorbitol, crystallising

Section 6.3: Shelf life                        - editorial changes

Section 6.4: Special precautions for use (new text I italics)     - After first opening: Keep the sachet tightly closed to protect from light.

Updated on 7 February 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product contains
  • Change to section 6 - date of revision
  • Change to name of medicinal product

Updated on 8 April 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2:
....
If these has been no response to Versatis after this period (during the wearing time and/or during the plaster-free interval) or if any relieving effect can solely be related to the skin protective properties of the plaster, treatment must be discontinued as potential risks may outweigh benefits in this context (see sections 4.4 and 5.1).

Section 4.8:
details on reporting suspected adverse reactions to HPRA

Dare of revision of text:
November 2014

Updated on 8 April 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 25 June 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.9 - Overdose
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 2 - clarification of text
Section 4.1 - addition of 'in adults' as part of the indication
Section 4.3 - cross reference to Section 6.1
Section 4.6 - section titles and addition of statement on fertility data
Section 4.9 - addition of comma
Section 9 - dates of authorisations updated
Section 10 - date updated

Updated on 21 June 2013 PIL

Reasons for updating

  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to improve clarity and readability

Updated on 3 February 2012 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 30 January 2012 PIL

Reasons for updating

  • Change to how the medicine works
  • Change to date of revision

Updated on 30 January 2012 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

SPC section 4.2 – statement on long-term use, use in renally impaired patients, use in hepatically impaired patients, data related to children

SPC section 4.6 –statement updated related to animal data

SPC section 5.1 – update to statement on mechanism of action, updates to clinical data information and clarity of data

SPC section 5-2 - typographic

SPC section 5.3 – update to statements on toxicity, embryo-foetal development, male fertility

SPC section 10 - date

Updated on 22 December 2011 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company


5.1. - Amending the text to describe the pain relief on a six point scale

10 - updating date

Updated on 12 December 2011 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2 - added: . The plaster can be applied during the day or during the night.

10 - date changed to 25/11/2011

Updated on 8 December 2011 PIL

Reasons for updating

  • Change to date of revision
  • Change to dosage and administration
  • Change to MA holder contact details

Updated on 27 June 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8
Rewording of adverse events to state:
The most commonly reported adverse reactions were administration site reactions (such as burning, dermatitis, erythema, pruritus, rash, skin irritation, and vesicles).

Section 10
Date updated:
21/06/2011

Updated on 22 December 2010 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 17 December 2010 PIL

Reasons for updating

  • New PIL for new product